Home
Home

cladribine

With cladribine gone, Gilenya takes center stage

With cladribine gone, Gilenya takes center stage
Fierce Pharma

Merck KGaA Slides After Decision Not to Seek MS Drug Approval

Merck KGaA Slides After Decision Not to Seek MS Drug Approval
Bloomberg

News

Merck KGaA Drug Fails to Convince FDA
WSJ Online

News

FDA's Top Q4 Blockbuster Drug Decisions
Fierce Biotech
»

News

A Busy Week for Multiple Sclerosis News
Seeking Alpha
»

News

Merck considers appeal of MS drug rejection
Financial Times, UK
»

News

Merck KGaA's Cladribine Multiple Sclerosis Pill Gets Faster Review in U.S.
Bloomberg
»

News

Merck KGaA expects MS pill to lift drugs margin
Reuters
»

News

Merck KGaA again seeks U.S. nod for MS pill
Reuters
»

News

Merck KGaA Pill Cuts MS Relapse Risk in Half, With Side Effects
Bloomberg
»